Trials / Completed
CompletedNCT01483534
Innovative Pulmonary Solutions (IPS) System for Targeted Lung Denervation
Evaluation of the Innovative Pulmonary Solutions (IPS) System for Targeted Lung Denervation (TLD) Therapy in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) - A Safety Study
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Nuvaira, Inc. · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety of Targeted Lung Denervation Therapy (or TLD TherapyTM) in patients suffering from COPD. Technical feasibility of the IPS SystemTM will also be evaluated through confirmation of successful application of TLD Therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | TLD Therapy (IPS SystemTM) | Targeted Lung Denervation Therapy will be achieved bronchoscopically. As this is a single-arm, non-randomized study, it is anticipated that all patients who provide written informed consent and meet the protocol entry criteria will undergo treatment. |
Timeline
- Start date
- 2011-10-01
- Primary completion
- 2013-11-01
- Completion
- 2015-11-01
- First posted
- 2011-12-01
- Last updated
- 2016-09-23
Locations
3 sites across 2 countries: Netherlands, South Africa
Source: ClinicalTrials.gov record NCT01483534. Inclusion in this directory is not an endorsement.